(Q42611184)

English

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study

scientific article published on October 2003

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

Elliott M Antman

2

object named as

Elliott M Antman

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Robert A Harrington

6

object named as

Robert A Harrington

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Nathan R. Every

5

object named as

Nathan R Every

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

James J Ferguson

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Eric R Bates

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Marc Cohen

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Carl J Pepine

7

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Pierre Theroux

8

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

NICE-3 Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

language of work or name

0 references

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

146

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

628-634

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Combination therapy with tirofiban and enoxaparin in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900165-0

7 January 2021

Identifiers

10.1016/S0002-8703(03)00165-0

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42611184&oldid=2098430723"